MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Anti-glutamic acid decarboxylase associated encephalitis presenting with new onset movement disorder after COVID-19 infection

    PY. Chen (Taipei, Taiwan)

    Objective: To describe the unusual clinical manifestations in a patient with coronavirus disease 2019 (COVID-19). Background: Movement disorders are uncommon neurological manifestations of severe acute…
  • 2023 International Congress

    Referral patterns from primary care physicians to specialists among people with Parkinson’s disease or a Parkinson’s disease–related disorder

    A. Patel, K. Jinnett, A. Gaur, E. Mearns, B. Cobb, C. Macaluso, J. Weiss, H. Lin, N. Win (South San Francisco, USA)

    Objective: To evaluate referral patterns to a specialist by a primary care provider (PCP) or other healthcare provider (HCP) among people diagnosed with Parkinson’s disease…
  • 2023 International Congress

    Impact of the severity of Parkinson’s disease on skin elasticity

    SY. You, HJ. Park (Daegu, Republic of Korea)

    Objective: To investigate changes in skin elasticity according to the severity of symptoms of Parkinson's disease. Background: Parkinson's disease (PD) is a neurodegenerative disease caused…
  • 2023 International Congress

    Path To Prevention (P2P) Therapeutics Platform Trial in Biomarker Defined Prodromal Parkinson’s Disease: Study Design

    C. Coffey, A. Siderowf, C. Tanner, K. Marek, M. Brumm, T. Simuni, P. Investigators, S. Chowdhury, T. Sherer, C. Kopil, K. Kieburtz, B. Saville, C. Allen-Savietta, B. Wendelberger, A. Crawford, K. Fabrizio ()

    Objective: To describe the study design and proposed timeline of the first interventional study in  biomarker defined prodromal Parkinson’s Disease (PD). Background: P2P is a…
  • 2023 International Congress

    Potential treatment for CMT2S caused by IGHMBP2 cryptic splice variant, with ASO based therapeutic

    S. Smieszek, C. Tyner, A. Kaden, C. Johnson, C. Polymeropoulos, G. Birznieks, M. Polymeropoulos (Washington, USA)

    Objective: Our objective was to target a specific cryptic splice site variant affecting immunoglobulin mu‐binding protein 2 (IGHMBP2) protein levels with a novel antisense oligonucleotide…
  • 2023 International Congress

    Dance for Parkinson’s disease to improve gait and balance: clinical assessments vs. objective measures.

    HHN. Kalyani, K. Sullivan, G. Moyle, S. Brauer, E. Jeffrey, G. Kerr (Colombo, Sri Lanka)

    Objective: To evaluate how the dance classes based on the Dance for Parkinson’s Disease®(DfPD®) model could improve gait and balance in people with Parkinson’s disease…
  • 2023 International Congress

    Update on the ADOPTION Study: Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This exploratory trial aims to compare treatment outcomes of adding one daily dose of opicapone (OPC) 50 mg versus an additional dose of levodopa…
  • 2023 International Congress

    Functional connectivity fingerprints in Parkinson’s disease patients with hallucinations

    S. Stampacchia, F. Bernasconi, J. Potheegadoo, J. Pagonabarraga, J. Kulisevsky, D. van Deville, E. Amico, O. Blanke (Geneve, Switzerland)

    Objective: Investigate functional connectivity (FC) fingerprints of Minor Hallucinations (MH) in Parkinson’s Disease (PD). Background: MHs occur at the early stages of Parkinson’s disease in…
  • 2023 International Congress

    Case report on the use of a High Frequency Vibrotactile Stimulation and Cueing Device over 4 months in a patient with Parkinson’s Disease and refractory symptoms

    A. Mackett (Cambridge, United Kingdom)

    Objective: To document motor symptoms of a patient with PD whilst using a Focussed Vibrotactile Stimulation and Cueing Device (FVCD). Background: A 77-year-old patient with…
  • 2023 International Congress

    Genetic study of early-onset Parkinson’s disease in the Malaysian population

    YW. Tay, AH. Tan, JL. Lim, K. Lohmann, K. Azmi Ibrahim, Z. Abdul Aziz, YT. Chin, AS. Mawardi, TT. Lim, I. Looi, YK. Chia, JCE. Ooi, WK. Cheah, A. Dy Closas, LC. Lit, JW. Hor, TS. Toh, K. Muthusamy, P. Bauer, V. Skrahin, A. Rolfs, C. Klein, A. Ahmad-Annuar, SY. Lim (Kuala Lumpur, Malaysia)

    Objective: This study aimed to investigate the genetic architecture of EOPD in a multi-ethnic Malaysian cohort. Background: About 5-10% of Parkinson’s disease (PD) cases are…
  • « Previous Page
  • 1
  • …
  • 94
  • 95
  • 96
  • 97
  • 98
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley